日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Improving saccharification of ramie stalks by synergistic effect of in-house cellulolytic enzymes consortium

利用内部纤维素酶联合体的协同作用提高苎麻茎的糖化率

Cao, Cha; Zhu, Zuohua; Xu, Chao; Gong, Wenbing; Zhou, Yingjun; Yan, Li; Hu, Zhenxiu; Xie, Chunliang; Peng, Yuande

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

肺癌中 EGFR 外显子 19 缺失突变的等位基因特异性激活、酶动力学和抑制剂敏感性

Benjamin P Brown, Yun-Kai Zhang, Soyeon Kim, Patrick Finneran, Yingjun Yan, Zhenfang Du, Jiyoon Kim, Abigail Leigh Hartzler, Michele L LeNoue-Newton, Adam W Smith, Jens Meiler, Christine M Lovly

Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

致癌 EGFR 激酶结构域重复的结构功能分析揭示了激活的见解和治疗靶向的潜在方法

Zhenfang Du #, Benjamin P Brown #, Soyeon Kim, Donna Ferguson, Dean C Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean-Nicolas Gallant, Yun-Kai Zhang, Yingjun Yan, Monica Red-Brewer, Siraj M Ali, Alexa B Schrock, Ahmet Zehir, Marc Ladanyi, Adam W Smith, Jens Meiler, Christine M Lovly

Bioactive constituents of Salvia przewalskii and the molecular mechanism of its antihypoxia effects determined using quantitative proteomics

利用定量蛋白质组学研究甘肃鼠尾草的生物活性成分及其抗缺氧作用的分子机制

Yafeng Wang, Delong Duo, Yingjun Yan, Rongyue He, Shengbiao Wang, Aixia Wang, Xinan Wu

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

对突变选择性 EGFR 抑制剂奥希替尼的靶向耐药性可以以等位基因特异性的方式产生,具体取决于原始 EGFR 激活突变

Benjamin P Brown #, Yun-Kai Zhang #, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfang Du, Jarrod A Smith, Jeffrey S Ross, Vincent A Miller, Siraj Ali, Lyudmila Bazhenova, Alexa B Schrock, Jens Meiler, Christine M Lovly

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

SFK/FAK 信号传导减弱奥希替尼在 EGFR 突变肺癌药物敏感和药物耐药模型中的疗效

Eiki Ichihara, David Westover, Catherine B Meador, Yingjun Yan, Joshua A Bauer, Pengcheng Lu, Fei Ye, Amanda Kulick, Elisa de Stanchina, Robert McEwen, Marc Ladanyi, Darren Cross, William Pao, Christine M Lovly

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

EGFR 融合作为肺癌的新治疗靶点

Kartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, Francis J Giles, Barbara J Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K Owonikoko, Vijay Peddareddigari, Suresh S Ramalingam, Satyanarayan K Reddy, Beth Eaby-Sandy, Tiziana Vavalà, Andrew Whiteley, Heidi Chen, Yingjun Yan, Jonathan H Sheehan, 

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

在 ALK 融合阳性肺癌中同时靶向 IGF-1R 和 ALK 的原理

Christine M Lovly, Nerina T McDonald, Heidi Chen, Sandra Ortiz-Cuaran, Lukas C Heukamp, Yingjun Yan, Alexandra Florin, Luka Ozretić, Diana Lim, Lu Wang, Zhao Chen, Xi Chen, Pengcheng Lu, Paul K Paik, Ronglai Shen, Hailing Jin, Reinhard Buettner, Sascha Ansén, Sven Perner, Michael Brockmann, Marc Bos